Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 15/20 | 0.85 |
| ▸ | CDK1 | P06493 | 14/20 | 0.85 |
| ▸ | CCND1 | P24385 | 13/20 | 0.85 |
| ▸ | CDK2 | P24941 | 12/20 | 0.85 |
| ▸ | CDK9 | P50750 | 12/20 | 0.85 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.85 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.85 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.85 |
| ▸ | CCNB2 | O95067 | 7/20 | 0.85 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 0.85 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.85 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.85 |
| ▸ | GSK3A | P49840 | 4/20 | 0.85 |
| ▸ | CCND3 | P30281 | 4/20 | 0.85 |
| ▸ | CDK7 | P50613 | 3/20 | 0.85 |
| ▸ | CCNH | P51946 | 2/20 | 0.85 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.85 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 0.85 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.85 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179591 | 1.00 | CDK4 (0.85) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL290572 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL17348307 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL665748 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL31702788 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL23683025 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL291157 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL665749 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL29777523 | 0.92 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 | |
| Riviciclib SCHEMBL290347 | 0.91 | CDK4 (1.00) | CDK4CDK1CCND1CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | claimed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | claimed |
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | disclosed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | CCNI, CDK1, CCNA1 | CDK4 7/4885CDK1 2/4885CCND1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.